T-cell Large Granular Lymphocyte Leukemia (T-LGL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
T-cell large granular lymphocyte leukemia (T-LGL) is a heterogeneous lymphoproliferative disorder of CD3-positive T cells. The median age of T-LGL diagnosis is 60, with an equal male-to-female ratio and an indolent clinical course. A positive rheumatoid factor is found in 60%, polyclonal hypergammaglobulinemia in 10–40%, and a positive Coombs test in 15% of patients. The diagnostic criteria for LGL include a persistent increase in circulating LGLs, confirmatory immunophenotype, and, ideally clonal T cell receptor (TCR) rearrangements. T-LGL leukemia has a mature T cell immunophenotype, with 80% of patients expressing CD3, CD8, and TCRab, but not CD4, and discrepant weak CD5 or CD7 expression. Rare variants may be CD4þ and CD8– or co-expression of CD4 and CD8. Large granular lymphocytes form part of the cellular immune response and produce tumor necrosis factor a and interferon g, leading to cell lysis of damaged cells, such as virally infected cells. Secondary to chronic activation of T cells by viral infection or autoantigen found in rheumatoid arthritis, leading to expansion of an unstable T-LGL population at risk of leukemogenic transformation and uncontrolled cytokine production.
·
The incidence of LGL leukemia ranges from 0.2
to 0.5 cases per one million individuals. The median age at diagnosis is 66.5
years; females are likely to be diagnosed three years earlier compared with
males.
Thelansis’s “T-cell Large Granular
Lymphocyte Leukemia (T-LGL) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential T-cell
Large Granular Lymphocyte Leukemia (T-LGL) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of T-cell Large Granular Lymphocyte Leukemia (T-LGL) across 8 MM market from
the centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
T-cell Large Granular Lymphocyte
Leukemia (T-LGL) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has
been established based on a deep understanding of the pharma/biotech business
environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment